{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:55:05Z","timestamp":1791428105651,"version":"4.3.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:00:00Z","timestamp":1332288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s10549-012-2021-9","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T13:57:16Z","timestamp":1332251836000},"page":"353-362","source":"Crossref","is-referenced-by-count":84,"title":["Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study"],"prefix":"10.1007","volume":"134","author":[{"given":"Florentia","family":"Fostira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianthi","family":"Tsitlaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroulio","family":"Pertesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Timotheadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra V.","family":"Stavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Glentis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Bournakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattheos","family":"Bobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Pectasides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Papakostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Skarlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epaminontas","family":"Samantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bafaloukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paris A.","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Koutras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drakoulis","family":"Yannoukakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Konstantopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,21]]},"reference":[{"issue":"1","key":"2021_CR1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","volume":"52","author":"JS Reis-Filho","year":"2008","unstructured":"Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52(1):108\u2013118","journal-title":"Histopathology"},{"issue":"20","key":"2021_CR2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948","journal-title":"N Engl J Med"},{"issue":"18","key":"2021_CR3","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","volume":"44","author":"WJ Irvin Jr","year":"2008","unstructured":"Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44(18):2799\u20132805","journal-title":"Eur J Cancer"},{"issue":"24","key":"2021_CR4","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1158\/1078-0432.CCR-08-1208","volume":"14","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24):8010\u20138018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2021_CR5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.molonc.2010.04.006","volume":"4","author":"F Podo","year":"2010","unstructured":"Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, S\u00f8rlie T, Tagliabue E, B\u00f8rresen-Dale AL, FEMME Consortium (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4(3):209\u2013229","journal-title":"Mol Oncol"},{"issue":"6797","key":"2021_CR6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, L\u00f8nning PE, B\u00f8rresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"issue":"Suppl 1","key":"2021_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1634\/theoncologist.2011-S1-61","volume":"16","author":"CM Perou","year":"2011","unstructured":"Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl 1):61\u201370","journal-title":"Oncologist"},{"issue":"12","key":"2021_CR8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","volume":"7","author":"L Carey","year":"2010","unstructured":"Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683\u2013692","journal-title":"Nat Rev Clin Oncol"},{"issue":"15 Pt 1","key":"2021_CR9","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2021_CR10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721\u20131728","journal-title":"Cancer"},{"issue":"24","key":"2021_CR11","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1158\/1078-0432.CCR-08-1211","volume":"14","author":"OI Olopade","year":"2008","unstructured":"Olopade OI, Grushko TA, Nanda R, Huo D (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14(24):7988\u20137999","journal-title":"Clin Cancer Res"},{"issue":"27","key":"2021_CR12","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2008.19.6873","volume":"27","author":"D Huo","year":"2009","unstructured":"Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27(27):4515\u20134521","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021_CR13","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/cncr.25862","volume":"117","author":"KC Amirikia","year":"2011","unstructured":"Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women : implications for breast cancer screening recommendations. Cancer 117(12):2747\u20132753","journal-title":"Cancer"},{"issue":"5645","key":"2021_CR14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643\u2013646","journal-title":"Science"},{"issue":"6","key":"2021_CR15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4161\/cbt.3.6.840","volume":"3","author":"FJ Couch","year":"2004","unstructured":"Couch FJ (2004) Genetic epidemiology of BRCA1. Cancer Biol Ther 3(6):509\u2013514","journal-title":"Cancer Biol Ther"},{"issue":"26","key":"2021_CR16","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282\u20134288","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021_CR17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00432-010-0957-x","volume":"137","author":"TC Ruijter de","year":"2011","unstructured":"de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137(2):183\u2013192","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2021_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-007-9708-3","volume":"110","author":"WF Li","year":"2008","unstructured":"Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110(1):99\u2013109","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2021_CR19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.breast.2006.12.003","volume":"16","author":"A Musolino","year":"2007","unstructured":"Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A (2007) BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast 16(3):280\u2013292","journal-title":"Breast"},{"issue":"19","key":"2021_CR20","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","volume":"95","author":"WD Foulkes","year":"2003","unstructured":"Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482\u20131485","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"2021_CR21","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","volume":"11","author":"SR Lakhani","year":"2005","unstructured":"Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kr\u00e4mling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF, Breast Cancer Linkage Consortium (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175\u20135180","journal-title":"Clin Cancer Res"},{"issue":"43","key":"2021_CR22","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","volume":"25","author":"NC Turner","year":"2006","unstructured":"Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25(43):5846\u20135853","journal-title":"Oncogene"},{"issue":"14","key":"2021_CR23","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","volume":"26","author":"NC Turner","year":"2006","unstructured":"Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN (2006) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14):2126\u20132132","journal-title":"Oncogene"},{"issue":"8","key":"2021_CR24","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/0008-5472.CAN-08-4016","volume":"69","author":"E Alli","year":"2009","unstructured":"Alli E, Sharma VB, Sunderesakumar P, Ford JM (2009) Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69(8):3589\u20133596","journal-title":"Cancer Res"},{"issue":"10","key":"2021_CR25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer 4(10):814\u2013819","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2021_CR26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/PAS.0b013e31819c1c93","volume":"33","author":"LC Collins","year":"2009","unstructured":"Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE (2009) Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 33(7):1093\u20131097","journal-title":"Am J Surg Pathol"},{"key":"2021_CR27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","volume":"9","author":"SR Young","year":"2009","unstructured":"Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86","journal-title":"BMC Cancer"},{"issue":"5","key":"2021_CR28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082\u20131089","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2021_CR29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmedgenet-2011-100006","volume":"48","author":"DG Evans","year":"2011","unstructured":"Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM (2011) Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 48(8):520\u2013522","journal-title":"J Med Genet"},{"issue":"1","key":"2021_CR30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-011-1433-2","volume":"129","author":"E Comen","year":"2011","unstructured":"Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M (2011) Relative contributions of BRCA1 and BRCA2 mutations to \u201ctriple-negative\u201d breast cancer in Ashkenazi Women. Breast Cancer Res Treat 129(1):185\u2013190","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2021_CR31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10549-007-9571-2","volume":"107","author":"I Konstantopoulou","year":"2008","unstructured":"Konstantopoulou I, Rampias T, Ladopoulou A, Koutsodontis G, Armaou S, Anagnostopoulos T, Nikolopoulos G, Kamakari S, Nounesis G, Stylianakis A, Karanikiotis C, Razis E, Gogas H, Keramopoulos A, Gaki V, Markopoulos C, Skarlos D, Pandis N, Bei T, Arzimanoglou I, Fountzilas G, Yannoukakos D (2008) Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast\/ovarian cancer patients. Breast Cancer Res Treat 107(3):431\u2013441","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2021_CR32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.bjc.6605115","volume":"101","author":"S Armaou","year":"2009","unstructured":"Armaou S, Pertesi M, Fostira F, Thodi G, Athanasopoulos PS, Kamakari S, Athanasiou A, Gogas H, Yannoukakos D, Fountzilas G, Konstantopoulou I (2009) Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. Br J Cancer 101(1):32\u201337","journal-title":"Br J Cancer"},{"issue":"11","key":"2021_CR33","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdi366","volume":"16","author":"G Fountzilas","year":"2005","unstructured":"Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Siafaka V, Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P, Razis E, Makrantonakis P, Aravantinos G, Christodoulou C, Dimopoulos AM (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16(11):1762\u20131771","journal-title":"Ann Oncol"},{"issue":"5","key":"2021_CR34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/annonc\/mdm539","volume":"19","author":"G Fountzilas","year":"2008","unstructured":"Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, Dimopoulos AM, Hellenic Cooperative Oncology Group (2008) Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10\/00. Ann Oncol 19(5):853\u2013860","journal-title":"Ann Oncol"},{"issue":"4","key":"2021_CR35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1385\/MO:23:4:479","volume":"23","author":"G Fountzilas","year":"2006","unstructured":"Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E, Economopoulos T, Papakostas P, Papadimitriou C, Gogas H, Efstratiou I, Skarlos D (2006) Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol 23(4):479\u2013488","journal-title":"Med Oncol"},{"issue":"5","key":"2021_CR36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/07357900701829785","volume":"26","author":"CA Papadimitriou","year":"2008","unstructured":"Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G (2008) Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Cancer Invest 26(5):491\u2013498","journal-title":"Cancer Invest"},{"issue":"1","key":"2021_CR37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-008-0047-9","volume":"115","author":"G Fountzilas","year":"2009","unstructured":"Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115(1):87\u201399","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2021_CR38","first-page":"216","volume":"27","author":"D Pectasides","year":"2011","unstructured":"Pectasides D, Kotoula V, Fountzilas H, Korantzis I, Koutras A, Dimopoulos AM, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP, Kalogeras KT, Fountzilas G (2011) Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) study. Oncol Rep 27(1):216\u2013224","journal-title":"Oncol Rep"},{"issue":"9","key":"2021_CR39","first-page":"3007","volume":"31","author":"G Fountzilas","year":"2011","unstructured":"Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM (2011) Paclitaxel and bevacizumab, as first line combined treatment, in patients with metastatic breast cancer. The Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res 31(9):3007\u20133018","journal-title":"Anticancer Res"},{"issue":"3","key":"2021_CR40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1988","unstructured":"Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2021_CR41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ejca.2006.09.021","volume":"43","author":"S Armaou","year":"2007","unstructured":"Armaou S, Konstantopoulou I, Anagnostopoulos T, Razis E, Boukovinas I, Xenidis N, Fountzilas G, Yannoukakos D (2007) Novel genomic rearrangements in the BRCA1 gene detected in Greek breast\/ovarian cancer patients. Eur J Cancer 43(2):443\u2013453","journal-title":"Eur J Cancer"},{"issue":"8","key":"2021_CR42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","volume":"20","author":"A Goldhirsch","year":"2009","unstructured":"Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319\u20131329","journal-title":"Ann Oncol"},{"issue":"1","key":"2021_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","volume":"109","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25\u201332","journal-title":"Cancer"},{"issue":"5","key":"2021_CR44","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","volume":"14","author":"MC Cheang","year":"2008","unstructured":"Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368\u20131376","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2021_CR45","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480\u20131490","journal-title":"J Clin Oncol"},{"key":"2021_CR46","doi-asserted-by":"crossref","unstructured":"Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996 (1996) J Clin Oncol 14(5):1730\u20131736 (discussion 1737\u20131740)","DOI":"10.1200\/JCO.1996.14.5.1730"},{"issue":"11","key":"2021_CR47","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","volume":"94","author":"DM Euhus","year":"2002","unstructured":"Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G (2002) Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94(11):844\u2013851","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2021_CR48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12687-011-0042-4","volume":"2","author":"D Gadzicki","year":"2011","unstructured":"Gadzicki D, Evans DG, Harris H, Julian-Reynier C, Nippert I, Schmidtke J, Tibben A, van Asperen CJ, Schlegelberger B (2011) Genetic testing for familial\/hereditary breast cancer\u2014comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2(2):53\u201369","journal-title":"J Community Genet"},{"issue":"27","key":"2021_CR49","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","volume":"28","author":"JS Kwon","year":"2010","unstructured":"Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214\u20134220","journal-title":"J Clin Oncol"},{"issue":"9064","key":"2021_CR50","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(96)10109-4","volume":"349","author":"Breast Cancer Linkage Consortium","year":"1997","unstructured":"Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349(9064):1505\u20131510","journal-title":"Lancet"},{"issue":"8","key":"2021_CR51","first-page":"1588","volume":"58","author":"F Eisinger","year":"1998","unstructured":"Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, Longy M, Guinebretiere JM, Sauvan R, Noguchi T, Birnbaum D, Sobol H (1998) Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58(8):1588\u20131592","journal-title":"Cancer Res"},{"issue":"5","key":"2021_CR52","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4161\/cbt.2.5.511","volume":"2","author":"P Tisserand","year":"2003","unstructured":"Tisserand P, Fouquet C, Barrois M, Gallou C, Dendale R, Stoppa-Lyonnet D, Sastre-Garau X, Fourquet A, Soussi T (2003) Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Cancer Biol Ther 2(5):559\u2013563","journal-title":"Cancer Biol Ther"},{"issue":"Suppl 2","key":"2021_CR53","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1038\/modpathol.2010.37","volume":"23","author":"L Silva Da","year":"2010","unstructured":"Da Silva L, Lakhani SR (2010) Pathology of hereditary breast cancer. Mod Pathol 23(Suppl 2):S46\u2013S51","journal-title":"Mod Pathol"},{"issue":"2","key":"2021_CR54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O\u2019Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono J (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123\u2013134","journal-title":"N Engl J Med"},{"issue":"3","key":"2021_CR55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","volume":"364","author":"J O\u2019Shaughnessy","year":"2011","unstructured":"O\u2019Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205\u2013214","journal-title":"N Engl J Med"},{"issue":"3","key":"2021_CR56","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-1293-1","volume":"125","author":"SK Pal","year":"2011","unstructured":"Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3):627\u2013636","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2021_CR57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nbt0511-373","volume":"29","author":"M Guha","year":"2011","unstructured":"Guha M (2011) PARP inhibitors stumble in breast cancer. Nat Biotechnol 29(5):373\u2013374","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2021_CR58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2008.20.7019","volume":"28","author":"T Byrski","year":"2010","unstructured":"Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28(3):375\u2013379","journal-title":"J Clin Oncol"},{"issue":"7315","key":"2021_CR59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09339","volume":"467","author":"JS Bono de","year":"2010","unstructured":"de Bono JS, Ashworth A (2010) Translating cancer research into targeted therapeutics. Nature 467(7315):543\u2013549","journal-title":"Nature"},{"issue":"2","key":"2021_CR60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-007-9729-y","volume":"110","author":"T Anagnostopoulos","year":"2008","unstructured":"Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S, Kamakari S, Nasioulas G, Dobrovic A, Young MA, Mitchell G, Fountzilas G, Yannoukakos D (2008) A novel BRCA1 founder mutation G1738R related to breast-ovarian cancer predisposition, found in Greek patients. Breast Cancer Res Treat 110(2):377\u2013385","journal-title":"Breast Cancer Res Treat"},{"key":"2021_CR61","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1399-0004.2010.01532.x","volume":"80","author":"M Pertesi","year":"2011","unstructured":"Pertesi M, Konstantopoulou I, Yannoukakos D (2011) Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests that they are founder mutations for the Greek population. Clin Genet 80:375\u2013382","journal-title":"Clin Genet"},{"issue":"3","key":"2021_CR62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ng1197-341","volume":"17","author":"A Petrij-Bosch","year":"1997","unstructured":"Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Dr\u00fcsedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van \u2018t Veer LJ, Bakker E, van Ommen GJ, van Devilee P (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17(3):341\u2013345","journal-title":"Nat Genet"},{"issue":"2","key":"2021_CR63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0165-4608(01)00623-9","volume":"134","author":"\u0391 Ladopoulou","year":"2002","unstructured":"Ladopoulou \u0391, Konstantopoulou \u0399, Armaou S, Efstathiou E, Mihalatos M, Bardi G, Nasioulas G, Pandis N, Yannoukakos D (2002) A change in the last base of BRCA1 exon 23, 5586G>A, results in abnormal RNA splicing. Cancer Genet Cytogenet 134(2):175\u2013177","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2021_CR64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-010-0817-z","volume":"125","author":"MD Sluiter","year":"2011","unstructured":"Sluiter MD, van Rensburg EJ (2011) Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat 125(2):325\u2013349","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"2021_CR65","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","volume":"24","author":"BG Haffty","year":"2006","unstructured":"Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652\u20135657","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2021-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2021-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2021-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T21:38:20Z","timestamp":1561498700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2021-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,21]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2021-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,21]]}}}